Clinical Data Acquires Electa Lab; Cash Transaction Immediately Accretive to Earnings.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ:CLDA), announced today that it has acquired Electa Lab s.r.l. in a cash transaction valued at approximately $1.8 million. Electa Lab, headquartered in Forli, Italy, is a leading worldwide supplier of Erythrocyte Sedimentation Rate ("ESR") instrumentation and related consumables, with annual sales of more than $3 million. Electa Lab has also developed proprietary technology for the safe decapping of blood collection tubes and is developing instruments and assays for the immunochemistry and coagulation markets. The acquisition will be accounted for as a purchase and is expected to be immediately accretive to Clinical Data's earnings.

Israel M. Stein, MD, President and Chief Executive Officer of Clinical Data commented, "The acquisition of Electa Lab enhances our ability to provide a full range of products and services to smaller clinical laboratories worldwide. The market leading products developed and produced by Electa Lab are highly complementary to the diagnostic products already offered by our domestic and international subsidiaries and in many cases use the same distribution channels."

Mr. Renzo Montanari, Electa Lab's Founder and Managing Director stated, "We are very proud to be entering into the Clinical Data group of companies and are pleased that our ESR technology can now receive world-wide distribution. The goal of our company is to offer the standard of excellence in ESR diagnostics, and our acquisition by Clinical Data will help ensure the success of this endeavor. The synergy created by this acquisition will also foster the development of other novel and useful products for the clinical laboratory diagnostics market".

Clinical Data will continue to hold non-exclusive distribution rights to the ESR products manufactured by Diesse Diagnostica Senese, SpA, and will continue to provide sales, service and technical support to Clinical Data customers using Diesse ESR products in the United States.

About Clinical Data, Inc.

Clinical Data, Inc. is a worldwide leader in developing and commercializing pharmacogenomics and clinical diagnostics to improve patient care. The Company's genomic services are marketed to the pharmaceutical, biotech, clinical, academic and agricultural marketplaces. The Company is utilizing pharmacogenomics to develop molecular diagnostics and more efficacious therapeutics by finding genetic markers to guide drug development and utilization. Its diagnostic and instrumentation business has a market focus on the physician's office, hospital and small-to-medium sized laboratory segments.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking statements that are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed and identified in public filings with the U.S. Securities and Exchange Commission made by CLDA; significant acquisitions or divestitures by major competitors; our ability to achieve expected synergies and operating efficiencies in all of our acquisitions, and to successfully integrate our operations; our expectations regarding the timing, completion and accounting and tax treatments of the transactions and the value of the transaction consideration; and general economic downturns. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's various SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2005, and 2004 and 2005 quarterly reports on Forms 10-QSB and 10-Q.